Emerging Bioelectric Research of HSD and S1‑Positive Monocyte Clinical Testing
By Jen Dillon, Electronic Homeopath Founder, Quantum Factor Research Initiative
Over the past several years, the HSD (Homeopathic Spike Detox) Study has documented a recurring pattern in individuals with persistent post‑COVID symptoms: the presence of S1‑positive monocytes and abnormalities across classical, intermediate, and nonclassical monocyte subsets. These findings mirror published research showing that fragments of SARS‑CoV‑2—particularly the S1 protein—may persist inside monocytes (white blood cells) long after infection.
What began as a grassroots observational study has now grown into a multi‑year research initiative with thousands of case reports. One of the most compelling recent cases involves a 71‑year‑old male with a complex post‑COVID history, two strokes, cardiomyopathy, and a bladder neoplasm. His clinical trajectory offers a window into the emerging field of bioelectric signaling and immune recovery.
This article summarizes his case chronologically, without inferring causality, and introduces the next evolution of the HSD protocol: Quantum Factor, now available as a retail wellness brand.
The HSD Study: What We’ve Been Observing
Since 2021, the HSD Study has documented:
• Persistent S1 protein in monocyte subsets
• Immune dysregulation patterns consistent with long‑COVID literature
• Fatigue, cognitive slowing, neurological symptoms, and reduced daily function
• Functional improvements reported during and after HSD protocols
• Shifts in monocyte subset profiles on follow‑up testing
The study has always been descriptive, not interventional. Participants self‑report their experiences while clinicians track immune markers such as the Incell Dx S1 Immune Subset Panel.
This case is one example of the patterns we continue to see.
Case Summary: A Complex Post‑COVID Trajectory
The patient’s history included:
• Three COVID‑19 infections
• New‑onset atrial fibrillation
• Cardiomyopathy with multiple stents
• A cerebellar stroke in 2023
• A frontal‑lobe stroke in 2025 with speech and word‑retrieval deficits
• Persistent fatigue and cognitive decline
• A bladder neoplasm identified during stroke recovery
Initial S1 testing “positively revealed S1 (spike protein) in his monocytes,” consistent with published findings of S1 persistence in CD16+ monocytes.
Monocyte subset abnormalities were also present.
The 8‑Week HSD Protocol: Reported Changes
The patient began the HSD Protocol on October 27, 2025.
After 4 Weeks
• Noticeable improvement in energy
• Reduced need for daytime naps
• Improved sleep
• Increased mental clarity
After 8 Weeks
• Continued improvement in energy
• Marked improvement in speech and word retrieval after his frontal‑lobe stroke
• Increased ability to engage in building and repair projects
• Greater cognitive‑motor capacity
A second round was recommended and initiated.
Follow‑Up Clinical Testing
Repeat Incell Dx testing showed:
Monocyte subset abnormalities also shifted toward normalization.
Again, these findings are presented descriptively, without inference of causality.
Unexpected Clinical Observation: Bladder Neoplasm (tumor)
In February 2026, the patient arrived for scheduled surgical removal of the bladder neoplasm. According to the intake summary:
No excision was performed.
This observation is included solely as part of the chronological clinical narrative.
Why This Case Matters
This case highlights several themes emerging from the HSD Study:
• S1‑positive monocytes may persist long after infection
• Monocyte subset abnormalities are common in long‑COVID cohorts
• Functional improvements may occur alongside shifts in immune markers
• Unexpected clinical findings warrant further investigation
The bioelectric dimension—how frequency‑based signaling may interact with immune regulation—is an area of growing interest and deserves rigorous study.
From HSD Study to Retail Brand: Introducing Quantum Factor
After years of observational research, practitioner feedback, and thousands of case reports, the HSD protocol has evolved into a next‑generation retail wellness line:
Quantum Factor
https://quantumfactor.net
Quantum Factor brings the core principles of the HSD protocol into a consumer‑ready format:
• Bioelectric frequency‑imprinted formulas
• No botanicals, pharmaceuticals, or biochemical actives
• Designed to support the body’s innate regulatory processes
• Developed from real‑world observational patterns
Quantum Factor is not a treatment, it’s a wellness system informed by the HSD Study’s bioenergetic research and designed for those seeking alternatives.
Looking Forward
The intersection of bioelectric signaling, immune dysregulation, and persistent S1 protein is an emerging field with enormous potential. As more clinicians begin testing for S1‑positive monocytes and tracking functional outcomes, we may gain clearer insight into recovery trajectories for individuals with complex post‑COVID presentations.
The HSD Study continues, and Quantum Factor now offers a way for individuals and practitioners to access the next evolution of this work.